STOCK TITAN
  1. Home
  2. News
  3. MRTX

Mirati Therapeutics Inc - MRTX STOCK NEWS

Welcome to our dedicated news page for Mirati Therapeutics (Ticker: MRTX), a resource for investors and traders seeking the latest updates and insights on Mirati Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Mirati Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Mirati Therapeutics's position in the market.

News
European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
Rhea-AI Summary
Mirati Therapeutics, Inc. (NASDAQ: MRTX) receives conditional marketing authorization from the European Commission for KRAZATI® (adagrasib) as a targeted treatment option for adult patients with KRASG12C-mutated advanced non-small cell lung cancer (NSCLC) and disease progression after at least one prior systemic therapy. The approval is based on the positive results from the Phase 2 registration-enabling cohort of the KRYSTAL-1 study, demonstrating an efficacious and tolerable therapeutic option for patients living with advanced KRASG12C-mutated NSCLC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
none
-
News
Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure
Rhea-AI Summary
Mirati Therapeutics, Inc. (NASDAQ: MRTX) receives positive opinion from CHMP for KRAZATI as a targeted treatment for KRASG12C-mutated NSCLC
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
none
-
News
Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
Rhea-AI Summary
Mirati Therapeutics, Inc.® (NASDAQ: MRTX) announced financial results for Q3 2023, including a net loss of $161.9 million and cash, cash equivalents, and short-term investments of $976.4 million as of September 30, 2023. The company reported net KRAZATI product revenue of $16.4 million for Q3 2023. Mirati also provided pipeline updates for its targeted oncology programs, including the conditional marketing authorization approval for KRAZATI in the UK for the treatment of advanced non-small cell lung cancer with KRASG12C mutation. Additionally, the company announced its pending acquisition by Bristol Myers Squibb for $58.00 per share in cash, totaling $4.8 billion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
earnings
News
Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
Rhea-AI Summary
Mirati Therapeutics has received conditional marketing authorization approval from the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) for KRAZATI® (adagrasib). The approval allows KRAZATI to be used as a monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) who have the KRASG12C mutation and have progressive disease after prior therapy with platinum-based chemotherapy and/or anti-PD-1/PD-L1 immunotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Mirati Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer (NSCLC)
Rhea-AI Summary
Mirati Therapeutics announces updated results from the KRYSTAL-7 Phase 2 study evaluating adagrasib combined with pembrolizumab in first-line NSCLC patients with KRASG12C mutation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.57%
Tags
none
-
News
Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics
Rhea-AI Summary
Bristol Myers Squibb to acquire Mirati for $4.8 billion in cash
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.09%
Tags
acquisition
News
Mirati To Present Updated Clinical Data at ESMO Congress 2023
Rhea-AI Summary
Mirati Therapeutics announces positive data on adagrasib in combination with pembrolizumab for NSCLC treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.99%
Tags
conferences clinical trial
-
News
Mirati Presents Two-Year Follow-Up Data from KRYSTAL-1 Study Demonstrating Durable Response and Long-Term Overall Survival at 2023 World Conference on Lung Cancer
Rhea-AI Summary
Mirati Therapeutics presents positive two-year follow-up data for adagrasib in KRASG12C-mutated NSCLC
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Rhea-AI Summary
Mirati Therapeutics grants equity awards to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.81%
Tags
none
News
Mirati Therapeutics Announces Departure of Chief Financial Officer Laurie Stelzer
Rhea-AI Summary
Mirati Therapeutics CFO to depart, interim CFO appointed
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.28%
Tags
none
Stock MRTX logo
Mirati Therapeutics Inc

Nasdaq:MRTX

MRTX Rankings

N/A Ranked by Market Cap
#3193 Ranked by Stock Gains
N/A Ranked by Dividends

MRTX Stock Data

4.12B
38.91M
1.72%
117.76%
6.26%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Diego

About MRTX

mirati therapeutics develops molecularly targeted, single agent and immuno-oncology combination therapies intended to treat cancer. mirati's approach combines the three most important factors in oncology drug development, 1) researching and developing drug candidates that target genetic and epigenetic drivers of cancer, 2) designing creative and agile clinical development strategies that select for patients whose tumors are dependent on specific driver alterations, and 3) leveraging a highly accomplished oncology precision medicine leadership team. the mirati team uses a blueprint – proven by their prior work – for developing potential breakthrough cancer therapies, with accelerated development paths, in order to improve outcomes for patients. mirati is advancing three drug candidates through clinical development for multiple oncology indications.